Senhwa's Silmitasertib Receives US FDA Orphan Drug Designati

/PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and...

Related Keywords

Australia , Taiwan , United States , California , Taipei , T Ai Pei , San Diego , South Korea , Canada , John Soong , Senhwa Biosciences , Senhwa Bioscience , Senhwa Biosciences Inc , Us National Institute Of Health , Drug Administration , Cancer Therapy Evaluation Program , Prnewswire Senhwa Biosciences Inc , Pediatric Brain Tumor Consortium , Orphan Drug Designation , Chief Medical Officer , Surgical Study , Therapy Evaluation Program , Fast Track Designation , Rare Pediatric Disease , Priority Review Voucher , Rare Pediatric Disease Designation , Sonic Hedgehog , Nc ,